BC Cancer

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Prostate cancer6 trials
• Lung cancer5 trials
• Head and neck cancer3 trials
• Pancreatic cancer3 trials
• Multiple myeloma2 trials
• Neuroendocrine tumours2 trials
• Sarcoma2 trials
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Colorectal cancer1 trial
• Diffuse large B-cell lymphoma1 trial
• Gastric and oesophageal cancer1 trial
• and 8 more

Phase

• Phase 23 trials
• Phase 33 trials
• Phase 1/22 trials
• Phase 11 trial

Status

• Recruiting7 trials
• Active, not recruiting6 trials
• Terminated2 trials
• Withdrawn2 trials
• Enrolling by invitation1 trial

Lead sponsor

• British Columbia Cancer Agency11 trials
• Elevation Oncology1 trial
• ESSA Pharmaceuticals1 trial
• European Myeloma Network B.V.1 trial
• Immunocore Ltd1 trial
• and 3 more

Running trials

• Recruiting

  Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life

  NCT07255001· British Columbia Cancer Agency· Source

  Contact: Daniel J Renouf, MD, MPH

• Recruiting

  Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

  NCT06574620· British Columbia Cancer Agency· Source

  Contact: Daniel J Renouf, MD

• Recruiting

  A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

  NCT06827613· Phase 1/2· Marengo Therapeutics, Inc.· Source

  Contact: Rahma Osman

• Recruiting

  Preliminary Assessment of [18F]BL40 in PET/CT Scans

  NCT06224309· British Columbia Cancer Agency· Source

  Contact: Pavithraa Ravi

• Enrolling by invitation

  177Lu-HTK03170 in mCRPC With PSMA Positive Disease

  NCT05570994· Phase 1/2· British Columbia Cancer Agency· Source

• Active, not recruiting

  Phase III Study of AK112 for NSCLC Patients

  NCT06396065· Phase 3· Summit Therapeutics· Source

• Recruiting

  Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  NCT05549297· Phase 3· Immunocore Ltd· Source

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· European Myeloma Network B.V.· Source

• Recruiting

  CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

  NCT05257967· British Columbia Cancer Agency· Source

  Contact: Cheryl Ho, MD

• Active, not recruiting

  [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer

  NCT04484701· British Columbia Cancer Agency· Source

• Recruiting

  Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

  NCT04273061· Phase 2· British Columbia Cancer Agency· Source

  Contact: Janessa Laskin, MD

• Active, not recruiting

  DOTATOC PET/CT for Imaging NET Patients

  NCT03583528· British Columbia Cancer Agency· Source

• Active, not recruiting

  Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer

  NCT03210103· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source

• Active, not recruiting

  PSMA PET/CT for Assessment of Recurrent Prostate Cancer

  NCT02899312· British Columbia Cancer Agency· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Pancreatic cancer2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Withdrawn

  Dynamic Whole Body PET/ MRI

  NCT04495959· British Columbia Cancer Agency· Source

• Withdrawn

  177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

  NCT04915144· Phase 2· British Columbia Cancer Agency· Source

• Terminated

  Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

  NCT04383210· Phase 2· Elevation Oncology· Source

• Terminated

  Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

  NCT04421222· Phase 1· ESSA Pharmaceuticals· Source